

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

THIS PAGE BLANK (USPTO)



(11) **EP 1180369 A1**

(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 158(3) EPC

(43) Date of publication:
20.02.2002 Bulletin 2002/08

(21) Application number: 00931546.6

(22) Date of filing: 24.05.2000

(51) IntCl.⁷: **A61K 39/395, A61K 45/00,**
A61K 31/519, A61K 31/506,
A61K 31/517, A61K 31/505,
A61K 31/5415, A61K 31/155,
A61P 37/06, A61P 29/00,
A61P 19/02
/(C07D 475/08, 403:10,
471:04, 239:95, 487:04, 239:48,
C07C 279:26)

(86) International application number:
PCT/JP00/03324

(87) International publication number:
WO 00/71160(30.11.2000 Gazette 2000/48)

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

(30) Priority: 24.05.1999 JP 14303399

(71) Applicant: Sankyo Company, Limited
Tokyo 103-8426 (JP)

(72) Inventors:
• Serizawa, Nobufusa Sankyo Company, Limited
Tokyo 140-8710 (JP)

• Ichikawa, Kimihisa Sankyo Company, Limited
Tokyo 140-8710 (JP)
• Yoshida, Hiroko Sankyo Company, Limited
Tokyo 140-8710 (JP)

(74) Representative: Gibson, Christian John Robert
MARKS & CLERK, 57/60 Lincoln's Inn Fields
London WC2A 3LS (GB)

(54) **MEDICINAL COMPOSITIONS CONTAINING ANTI-Fas ANTIBODY**

(57) The present invention provides a novel pharmaceutical composition containing an anti-Fas antibody which is useful as an agent for prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis.

More particularly, the present invention provides a pharmaceutical composition containing an anti-human Fas antibody having apoptosis inducing activity and a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity, as active ingredients.

According to the present invention, the amount of

the anti-Fas antibody to be used can be reduced in an agent for prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis, and thereby, the possibility that the patient becomes tolerant to anti-Fas antibody as a result of the production of antibodies against the anti-Fas antibody in the patient's body or the like can be decreased, and thus there can be provided a pharmaceutical composition of the present invention useful as an excellent agent for prophylaxis and/or treatment which can be used for a long time.

EP 1180369 A1

Description

TECHNICAL FIELD

[0001] The present invention relates to a novel pharmaceutical composition for prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis.

BACKGROUND ART

[0002] Physiological death of cells as a result of normal alternation of cells in a living organism is called apoptosis, and is distinguished from the pathological death of cells, i.e. necrosis [cf. Kerr et al., (1972), Br. J. Cancer, 26, 239]. Apoptosis is a kind of so-called programmed cell death, which is observed in certain cells that are programmed, in advance, to die in a living organism. Apoptosis is characterized by a curved cell surface, condensed nuclear chromatin and fragmented chromosomal DNA, among others.

[0003] Apoptosis plays a role in the differentiation of lymphocytes (T cells and B cells) by eliminating cells that recognize an autoantigen. It is believed that a cause of an autoimmune disease is the presence of auto-reactive lymphocytes generated due to failure of apoptosis in differentiation of lymphocytes [cf. Nakayama et al., (1995), Mediol, 12(10), 79-86].

[0004] Various molecules have been identified as being involved in apoptosis, including: Fas [cf. Yonehara, S., et al., (1989), J. Exp. Med., 169, 1747-1756]; tumor necrosis factor receptor [cf. Loetscher, H., et al., (1990), Cell, 61, 351-359]; CD40 [cf. Tsubata, T., et al., (1993), Nature, 364, 645-648]; and perforin/granzyme A [cf. Jenne, D. E., et al., (1988), Immunol. Rev. 103, 53-71]. Fas is a transmembrane protein present on the cellular surface, and binding of its extracellular domain to a protein called "Fas ligand" induces apoptosis in the cell.

[0005] It has been reported that some anti-Fas monoclonal antibodies have a cytotoxic activity and induce apoptosis in a cell in a similar manner as Fas ligand does, and thus they can be an agent for treating an autoimmune disease, AIDS, and neoplasm [cf. Japanese Patent Application Publication (Kokai) Hei 2-237935 and International application publication in Japan (Kohyo) Hei 5-503281].

[0006] On the other hand, rheumatism, especially rheumatoid arthritis is a disease that is accompanied by various abnormalities in immunology caused by internal and external factors, of which a basic pathological change is proliferation of synovial cells, and it is considered that it is a disorder of proliferation of the synovial cells accompanied by inflammatory cell infiltration and bone erosion. Tissue destruction around the joint suffering from rheumatoid arthritis is considered to be caused by abnormalities in the production of cytokines in inflammatory synovial cells. When the state of a joint of a rheumatic patient is investigated, there are observed an unusual proliferation of synovial cells, synovial villus proliferation, multilayered synovial cells and the like (cf. Daniel J. McCarty (1985) in "Arthritis and allied conditions, A textbook of rheumatology" 10th Edition, Lea & Febiger). An anti-inflammatory agent or an immunity regulatory agent, such as a steroid or the like is mainly used in pharmacotherapy that is presently carried out for rheumatism. However, if such excrescence of synovial cells can be controlled with a medicine, it is considered that such a medicine would be useful as an agent for treating rheumatism.

[0007] Incidentally, it is known that proliferation of the synovial cells in rheumatism is not out of control, but is spontaneously controlled (cf. Daniel J. McCarty (1985) in "Arthritis and allied conditions, A textbook of rheumatology" 10th Edition, Lea & Febiger). Furthermore, it has become clear recently that apoptosis is caused in synovial cells of a rheumatic patient and that Fas antigen appears on a membrane of the synovial cells. Nakajima et al. (cf. Nakajima, T., et al. (1995) Arthritis Rheum. 38, 485-491) and Aono et al. (cf. 38th Japan rheumatic society summary collection (1994), 487 page and Heisei 6 Japan cancer society general meeting reports 1994, 338 page) have studied whether apoptosis is induced in a synovial cell when the anti-human Fas antibody having a cytotoxic activity is added to the abnormally proliferating synovial cells originated from a rheumatic patient, and have found that apoptosis is induced at a higher rate in the abnormally proliferating synovial cells originated from a rheumatic patient, than in synovial cells which are not originated from a rheumatic patient. Accordingly, an anti-human Fas antibody can selectively induce apoptosis not only in a lymphocyte but also in the abnormally proliferating synovial cells, and therefore it is considered to be useful as an agent for rheumatism.

[0008] Several kinds of anti-human Fas mouse monoclonal antibodies have already been found (cf. Yonehara, S., et al (1989) J. Exp. Med. 169, 1747-1756, (1989); SCIENCE, 245, 301-305 (1989), and the like). Furthermore, as described above, it has been reported that the antibodies induce apoptosis in synovial cells of a rheumatic patient, in vitro (cf. 38th Japan rheumatic society summary collection (1994), p.487; and Japan cancer society general meeting reports (1994), p.338). Furthermore, some anti-Fas antibodies have been found to be effective and safe in treatment in an autoimmune disease model animal or a rheumatoid arthritis model animal (cf. European patent application publication No.0909816).

[0009] On the other hand, it is known that the effect of treatment for a rheumatoid arthritis patient can be increased

by using methotrexate and a monoclonal antibody cA2 against a tumor necrosis factor α (TNF α) together (Carden, the 7th international rheumatism symposium summary (1998) p.12-13). However, a synergistic effect of an anti-Fas antibody and methotrexate is not known at all.

[0010] If there is a compound which reinforces efficacy of an anti-Fas antibody useful as an agent for prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis, the amount of the anti-Fas antibody to be used can be decreased by using the compound and an anti-Fas antibody together. Thereby, the possibility that a patient becomes tolerant to anti-Fas antibody as a result of production of anti-Fas antibodies in the patient's body or the like can be decreased. Accordingly, there has been a need for a prophylactic or therapeutic agent consisting of a combination of an anti-Fas antibody and a compound reinforcing the efficacy of the anti-Fas antibody, which can be used for a long time.

DISCLOSURE OF THE INVENTION

[0011] The present invention relates to a pharmaceutical composition comprising an anti-human Fas antibody having an apoptosis inducing activity and a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity, as active ingredients. Preferably, the anti-human Fas antibody is a monoclonal antibody CH11, anti-human Fas monoclonal antibody HFE7A produced by a mouse-mouse hybridoma HFE7A (FERM BP-5828), or humanized antibodies thereof. Preferably, the above-mentioned compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity is selected from the group consisting of: methotrexate, edatrexate, epiroprim, iometrexol, pyritrexim, trimetrexate, brodimoprim, MX-68, N-[4-[3-(2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid, N-[[5-[2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]-pyrimidin-6-yl)ethyl-2-thienyl]carbonyl]-L-glutamic acid, (R)-N-[[5-[2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl-2-thienyl]carbonyl]-L-glutamic acid, N-((2,4-diamino-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl)-ethyl)-2-thienylcarbonyl-L-glutamic acid, (S)-2-[[[4-carboxy-4-[[[4-(2,4-diamino-6-pteridiny)l)methyl]amino]benzoyl]amino]butyl]amino]carbonyl]benzoic acid, N-[4-[3-(2,4-diamino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid, 2,4-diamino-6-(N-(4-(phenylsulfonyl)benzyl)methylamino)quinazoline, 2,4-diamino-5-[4-[3-(4-aminophenyl-4-sulfonylphenylamino)propoxy-3,5-dimethoxybenzyl]-pyrimidine, N-[4-[4-(2,4-diamino-5-pyrimidinyl)butyl]benzoyl]-L-glutamic acid, N-[4-[3-(2,4-diamino-5-pyrimidinyl)propyl]benzoyl]-L-glutamic acid, N-[4-[2-(2,4-diamino-6-pteridiny)ethyl]benzoyl]-4-methylene-DL-glutamic acid and N-(1-methylethyl)-N'[3-(2,4,5-trichlorophenoxy)propoxy]imidodicarbonimidicdiamidehydrochloride (PS15). Among them, methotrexate is the most preferable.

The inventors of the present invention have found that efficacy of the anti-Fas monoclonal antibody having an apoptosis inducing effect can be increased by using it together with a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity, and thereby have completed the present invention.


[0012] As used herein, the term "an apoptosis inducing activity" means an activity of inducing apoptosis in a cell expressing Fas on a cell membrane surface by binding to the Fas.

[0013] The anti-human Fas antibody used as the first active ingredient of the pharmaceutical composition of the present invention may be one of those that can be specifically bound to human Fas and has an apoptosis inducing effect. Preferable examples of such an anti-human Fas antibody include: anti-human Fas monoclonal antibody CH11 and anti-human Fas monoclonal antibody HFE7A produced by the mouse-mouse hybridoma HFE7A (FERM BP-5828), or humanized antibodies thereof (European patent application publication No. 0909816), but the present invention is not limited thereto. In addition, the anti-human Fas monoclonal antibody of the present invention also includes recombinants of these anti-human Fas monoclonal antibodies, which have an effect equivalent to these monoclonal antibodies. Moreover, in the present invention, there can also be used a so-called humanized antibody modified using a gene recombination technology so that the immunogenicity to humans may be reduced, without deteriorating the binding ability of the above-mentioned anti-Fas monoclonal antibody to bind to Fas and its apoptosis inducing activity.

[0014] As used herein, the term "the compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity" means a pharmaceutically acceptable compound which has an activity of antagonistically inhibiting metabolism of the folic acid that is an indispensable process in synthesis of DNA in a cell. Preferable examples of such a compound include:


Methotrexate(the following formula(I))

[0015]




Edatrexate(cf. British patent publication No. GB2058770B, the following formula(II))

[0016]




Epiroprim(cf. International patent application publication No. WO92/8461, the following formula (III))

[0017]




lometrexol(cf. International patent application publication No. WO86/5181 publication, the following formula (IV))

[0018]



Pyritrexim(cf. European patent publication No. 21292, the following formula (V))


[0019]



EP 1180369 A1


Trimetrexate (cf. British patent publication No. GB 1345502, the following formula (VI))

[0020]




Brodinoprim (cf. British patent publication No. GB 1449387, the following formula (VII))

[0021]




MX-68(International patent application publication No. WO97/34606, the following formula(VIII))

[0022]




N-[4-[3-(2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid(cf. J. Med. Chem. (1994)37, 1616-1624, the following formula(IX))

[0023]



N-[[5-[2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl-2-thienyl]carbonyl]-L-glutamic acid (cf. European patent publication No. 343801, the following formula(X))


[0024]



EP 1180369 A1

N-((2,4-diamino-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl)ethyl)-2-thienylcarbonyl-L-glutamic acid (cf. Summary of U.S. cancer research society, 88th annual convention (1997) No. 660, the following formula (XI))


[0025]



(XI)

(S)-2-[[[4-carboxy-4-[[4-[[[(2,4-diamino-6-pteridyl)methyl]amino]benzoyl]amino]-butyl]amino]carbonyl]benzoic acid (cf. European patent publication No. 345308, the following formula (XII))


[0026]



(XII)

N-[4-[3-(2,4-diamino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid (cf. European patent publication No. 334636, the following formula (XIII))


[0027]



(XIII)


2,4-diamino-6-(N-(4-(phenylsulfonyl)benzyl)methylamino)quinazoline(cf. Summary of U.S. cancer research society, annual convention (1992) No. 2458, the following formula (XIV))

[0028]




2,4-diamino-5-[4-[3-(4-aminophenyl-4-sulfonylphenylamino)propoxy-3,5-dimethoxybenzyl]pyrimidine(cf. European patent publication No. 231888, the following formula (XV))

[0029]




N-[4-[4-(2,4-diamino-5-pyrimidinyl)butyl]benzoyl]-L-glutamic acid (cf. International Patent Application No. WO95/9845, the following formula (XVI))

[0030]




N-[4-[3-(2,4-diamino-5-pyrimidinyl)propyl]benzoyl]-L-glutamic acid (cf. International Patent Application No. WO95/9845, the following formula (XVII))

[0031]




N-[4-[2-(2,4-diamino-6-pteridiny)ethyl]benzoyl]-4-methylene-DL-glutamic acid (cf. International Patent Application No. WO91/10666, the following formula (XVIII))

[0032]



N-(1-methylethyl)-N'[3-(2,4,5-trichlorophenoxy)propoxy]imidodicarbonimidicdiamidehydrochloride(PS15)(cf. International Patent Application No. WO93/16037, the following formula (XIX))

[0033]



[0034] It is known that all of these compounds have a folate antagonist activity or a dihydrofolate reductase inhibiting activity. Among the above-mentioned compounds, methotrexate is the most preferable as the compound that is to be contained in the pharmaceutical composition of the present invention.

[0035] The pharmaceutical composition of the present invention can be obtained by formulating an appropriate mixture of an anti-Fas monoclonal antibody having an activity of inducing apoptosis in cells expressing Fas and a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity.

[0036] The anti-Fas monoclonal antibody can be produced by methods known in the art using, for example, a molecule containing an extracellular domain of human Fas as an antigen. For example, the monoclonal antibody HFE7A that is one of the preferable anti-Fas monoclonal antibodies to be contained in the pharmaceutical composition of the present invention can be obtained by immunizing a Fas knock-out mouse with human Fas, subsequently fusing the spleen cells from the mouse with mouse myeloma cells, and culturing the resultant hybridoma. Specifically, it can be obtained according to the following method.

[0037] Preparation of a monoclonal antibody involves at least the following steps:

- (a) purification of a biomacromolecule for use as the antigen;
- (b) preparation of antibody producing cells, after immunizing an animal using injections of the antigen, bleeding the animal and assaying the antibody titer, in order to determine when to remove the spleen;
- (c) preparation of myeloma cells;
- (d) fusing the antibody producing cells and myeloma cells;
- (e) selecting a hybridoma producing an antibody of interest;
- (f) preparing a single cell clone (cloning);
- (g) optionally, culturing the hybridoma cells, or growing animals into which the hybridoma cells have been transplanted, for large scale preparation of the monoclonal antibody; and
- (h) testing the biological activities and the specificity, or assaying marker agent properties, of the monoclonal antibody thus prepared.

[0038] The method for the preparation of an anti-Fas monoclonal antibody is described below more in detail, in line with the above described steps. However, the method for preparing the antibody is not limited thereto. Other antibody producing cells than spleen cells and myeloma cells can also be used.

(a) Purification of antigen

[0039] A recombinant protein (hereinafter referred to as "recombinant human Fas"), effective as the antigen, can be obtained by transfecting the monkey cell line COS-1 with the expression vector pHFAS-AIC2, which encodes a fusion protein comprising the extracellular domain of human Fas and the extracellular domain of the mouse interleukin-3 receptor (hereinafter referred to as IL3R), [cf. Nishimura, Y., et al., (1995), J. Immunol., 154, 4395-4403] to express it, and collecting and partially purifying the expression product. The plasmid pHFas-AIC2 was constructed by inserting DNA encoding a human Fas and mouse IL3R fusion protein into pME18S, which is an expression vector for animal cells. As noted above, the materials used, such as the DNA encoding Fas, the vector and the host, are not restricted to those mentioned.

[0040] For example, the human Fas and mouse IL3R fusion protein produced in the culture supernatant of the transformed COS-1 cells transfected with the plasmid pHFas-AIC2 may be partially purified by ion-exchange chromatography using a Resource Q column (trade name; manufactured by Pharmacia).

[0041] Purified Fas obtained from the cell membranes of human cell lines can also be used as the antigen. Furthermore, since the primary structure of Fas is known [cf. Itoh, N., et al., (1991), Cell, 66, 233-243], a peptide comprising the amino acid sequence of SEQ ID NO: 1 of the Sequence Listing, may be chemically synthesized by a method well known in the art, and used as the antigen.

(b) Preparation of antibody producing cells

[0042] The immunogen produced in step (a) is mixed with an adjuvant, such as Freund's complete or incomplete adjuvant and alum, and an experimental animal is immunized therewith. A suitable experimental animal may be a Fas knock-out mouse, which may be produced by the method of Senju et al. [Senju, S., et al., (1996), International Immunology, 8, 423].

[0043] Suitable administration routes to immunize the mouse include the subcutaneous, intraperitoneal, intravenous, intradermal and intramuscular injection routes, with subcutaneous and intraperitoneal injections being preferred.

[0044] Immunization can be by a single dose or, by several repeated doses at appropriate intervals (preferably 1 to 5 weeks). Immunized animals are monitored for antibody titer in their sera, and an animal with a sufficiently high antibody titer is selected as the source of antibody producing cells. Selecting an animal with a high titer makes the subsequent process more efficient. Cells for the subsequent fusion are generally harvested from the animal 3 to 5 days after the final immunization.

[0045] Methods for assaying antibody titer include various well known techniques such as radioimmunoassay (hereinafter, referred to as RIA), solid-phase enzyme immunoassay (hereinafter, referred to as ELISA), fluorescent antibody assay and passive hemagglutination assay, with RIA and ELISA preferred for reasons of detection sensitivity, rapidity, accuracy and potential for automation.

[0046] Determination of antibody titer may be performed, for example, by ELISA, as follows. First, purified or partially purified Fas is adsorbed onto the surface of a solid phase, such as a 96-well ELISA plate, followed by blocking any remaining surface, to which Fas has not been bound, with a protein unrelated to the antigen, such as bovine serum albumin (hereinafter referred to as BSA). After washing, the well surfaces are contacted with serially diluted samples of the first antibody (for example, mouse serum) to enable binding of the anti-Fas antibody in the samples to the antigen. An enzyme-labeled, anti-mouse antibody, as the secondary antibody, is added to be bound to the mouse antibody. After washing, the substrate for the enzyme is added, and antibody titer can then be estimated by determining absorbance change due to color development caused by the decomposed substrate or the like.

(c) Preparation of myeloma cells

[0047] In general, cells from established mouse cell lines serve as the source of myeloma cells, for example, 8-azaguanine resistant mouse (derived from BALB/c) myeloma strains P3X63Ag8U.1 (P3-U1) [Yelton, D. E., et al., Current Topics in Microbiology and Immunology, 81, 1-7, (1978)], P3/NS1/1-Ag4-1 (NS-1) [Kohler, G., et al., European J. Immunology, 6, 511-519 (1976)], Sp2/0-Ag14 (SP-2) [Shulman, M., et al., Nature, 276, 269-270 (1978)], P3X63Ag8.653 (653) [Kearney, J. F., et al., J. Immunology, 123, 1548-1550 (1979)] and P3X63Ag8 (X63) [Horibata, K. and Harris, A. W., Nature, 256, 495-497 (1975)]. The cell line selected is subcultured in an appropriate medium, such as 8-azaguanine medium [RPMI-1640 medium supplemented with glutamine, 2-mercaptoethanol, gentamicin, fetal calf serum (hereinafter referred to as FCS), and 8-azaguanine], Iscove's Modified Dulbecco's Medium (hereinafter referred to as IMDM) or Dulbecco's Modified Eagle Medium (hereinafter referred to as DMEM). The cells are then subcultured in a normal medium, such as ASF 104 medium (Ajinomoto, K. K.) containing 10% FCS, 3 to 4 days prior to fusion, in order to ensure that at least 2×10^7 cells are available on the day of fusion.

(d) Cell fusion

[0048] The antibody producing cells to be used are plasma cells and lymphocytes which are their precursor cells, which may be obtained from any suitable part of the animal. Typical areas are spleen, lymph nodes, peripheral blood, or any appropriate combination thereof, spleen cells most commonly being used.

[0049] After the last booster injection, tissue in which antibody producing cells are present, such as the spleen, is enucleated from a mouse having the predetermined antibody titer to prepare antibody producing cells such as spleen cells. The currently favored technique for fusion of the spleen cells with the myeloma cells prepared in step (c), employs polyethylene glycol, which has relatively low cytotoxicity and the fusion procedure using it is simple. An example of this technique is as follows.

[0050] The spleen and myeloma cells are washed well with serum-free medium (such as RPMI 1640) or phosphate buffered saline (hereinafter referred to as PBS) and then mixed, so that the number ratio of spleen cells to myeloma cells is approximately between 5 : 1 and 10 : 1, and then centrifuged. After the supernatant has been discarded and the pelleted cells sufficiently loosened, 1 ml of serum-free medium containing 50% (w/v) polyethylene glycol (m.w. 1,000 to 4,000) is added dropwise with stirring. Subsequently, 10 ml of serum-free medium is slowly added and then the mixture centrifuged. The supernatant is discarded again, and the pelleted cells are suspended in an appropriate amount of HAT medium containing a solution of hypoxanthin, aminopterin and thymidine (hereinafter referred to as "HAT") and mouse interleukin-2 (hereinafter referred to as IL-2). The suspension is then dispensed into the wells of culture plates (hereinafter referred to as "plates") and incubated in the presence of 5% v/v CO₂ at 37°C for about 2 weeks; with the supplementary addition of HAT medium as appropriate.

(e) Selection of hybridomas

[0051] When the myeloma strain used is resistant to 8-azaguanine, i.e., it is deficient in the hypoxanthin guanine phosphoribosyl transferase (HGPRT) enzyme, any unfused myeloma cells and any myeloma-myeloma fusions are unable to survive in HAT medium. On the other hand, fusions of antibody producing cells with each other, as well as hybridomas of antibody producing cells with myeloma cells can survive, the former only having a limited life. Accordingly, continued incubation in HAT medium results in selection of only the desired hybridomas.

[0052] The resulting hybridomas grown up into colonies are then transferred into HAT medium without aminopterin (hereinafter referred to as "HT medium"). Thereafter, aliquots of the culture supernatant are collected to determine anti-Fas antibody titer by, for example, ELISA. When the above-mentioned fusion protein is used as the ELISA antigen, it is also necessary to eliminate clones producing an antibody which specifically binds to the extracellular domain of the mouse IL3 receptor. The presence or absence of such a clone may be verified, for example, by ELISA using the mouse IL3 receptor, or its extracellular domain, as the antigen.

[0053] Although the above selection procedure is exemplified using an 8-azaguanine resistant cell line, it will be appreciated that other cell lines may be used with appropriate modification to the media used.

(f) Cloning

[0054] Hybridomas which have been shown to produce specific antibodies, using a method similar to that described in the step (b) to determine antibody titer, are then transferred to another plate for cloning. Suitable cloning methods include: the limiting dilution method, in which hybridomas are diluted to contain one cell per well of a plate and then cultured; the soft agar method in which colonies are recovered after culturing in soft agar medium; a method of using a micromanipulator to separate a single cell for culture; and "sort-a-clone", in which single cells are separated by a cell sorter. Limiting dilution is generally the most simple and is commonly used.

[0055] The cloning procedure according to, for example, the limiting dilution method is repeated 2 to 4 times for each well demonstrating an antibody titer, and clones having stable antibody titers are selected as anti-Fas monoclonal antibody producing hybridomas. Hybridomas producing an anti mouse Fas antibody are selected by a similar method to obtain an anti-Fas monoclonal antibody producing cell line. A mouse Fas useful for this purpose, for example, is the fusion protein expressed by culturing animal cells transfected with the expression vector pME18S-mFas-AIC. This plasmid has DNA encoding a fusion protein comprising the extracellular domain of mouse Fas and the extracellular domain of the mouse IL3 receptor [cf. Nishimura, Y., et al., (1995). J. Immunol., 154, 4395-4403]. Other sources of murine Fas include purified mouse Fas and cells which express mouse Fas on their surface.

[0056] The mouse-mouse hybridoma HFE7A that produces the anti-Fas monoclonal antibody preferable as an active ingredient in the pharmaceutical composition of the present invention was deposited with the National Institute of Bioscience and Human-Technology at 1-3, Higashi 1-chome, Tsukuba, Ibaraki, Japan on February 19, 1997, in accordance with the Budapest Treaty on the Deposition of Microorganisms, and was accorded the accession number FERM BP-5828. Accordingly, when preparing an antibody using the mouse-mouse hybridoma HFE7A, the preparation may

be performed by following a procedure starting from the step (g) below, with the steps (a) to (f) omitted.

(g) Culture of hybridoma to prepare monoclonal antibody

[0057] The hybridoma obtained by the cloning is then cultured in normal medium, not in HT medium. Large-scale culture can be performed by roller bottle culture, using large culture bottles, or by spinner culture. The supernatant from the large-scale culture is purified by a suitable method, such as gel filtration, which is well known to those skilled in the art, to obtain an anti-Fas monoclonal antibody which the prophylactic or therapeutic agent of the present invention contains. The hybridoma may also be grown intraperitoneally in a syngeneic mouse, such as a BALB/c mouse or a Nu/Nu mouse, to obtain a large quantity of ascites containing an anti-Fas monoclonal antibody which the prophylactic or therapeutic agent of the present invention contains. Purification can also be conducted through use of commercially available monoclonal antibody purification kits (for example, MAb Trap GII Kit; Pharmacia).

[0058] Monoclonal antibodies prepared as above have a high specificity to human and mouse Fas.

(h) Assay of monoclonal antibody

[0059] Determination of the isotype and the subclass of the monoclonal antibody thus obtained may be performed as follows. Suitable identification methods include the Ouchterlony method, ELISA and RIA. The Ouchterlony method is simple, but requires concentration of the solution when the concentration of the monoclonal antibody is low. When ELISA or RIA is used, the culture supernatant can be reacted directly with an antigen adsorbed on a solid phase and with secondary antibodies having specificities for the various immunoglobulin isotypes and subclasses to identify the isotype and subclass of the monoclonal antibody. A method of using a commercial kit for identification, such as a Mouse Typer Kit (manufactured by Bio-Rad Laboratories, Inc.) is more simple.

[0060] Quantification of protein may be performed by the Folin-Lowry method, or by calculation based on the absorbance at 280 nm [$1.4(\text{OD}_{280}) = \text{immunoglobulin } 1 \text{ mg/ml}$].

[0061] DNA encoding the heavy and light chains of the anti-Fas monoclonal antibody that is preferable as an active ingredient in the pharmaceutical composition of the present invention, may be obtained by preparing mRNA from hybridoma cells producing the anti-Fas monoclonal antibody, converting the mRNA into cDNA with reverse transcriptase, and then isolating the DNA encoding the heavy and/or light chains of the antibody, respectively.

[0062] Extraction of mRNA can be performed by the guanidinium thiocyanate-hot phenol method, the guanidinium thiocyanate-guanidinium HCl method, or the like, but the guanidinium thiocyanate-cesium chloride method is preferred. Preparation of mRNA from cells is generally performed by first preparing total RNA and then purifying mRNA from the total RNA by using a poly(A)⁺ RNA purification matrix, such as oligo(dT) cellulose and oligo(dT) latex beads. Alternatively, mRNA may be prepared directly from a cell lysate using such a matrix. Methods for preparing total RNA include: alkaline sucrose density gradient centrifugation [cf. Dougherty, W. G. and Hiebert, E. (1980), *Virology*, 101, 466-474]; the guanidinium thiocyanate-phenol method; the guanidinium thiocyanate-trifluorocesium method; and the phenol-SDS method. The method using guanidinium thiocyanate and cesium chloride [cf. Chirgwin, J. M., et al., (1979), *Biochemistry*, 18, 5294-5299] is preferable.

[0063] The thus obtained poly(A)⁺ RNA can be used as the template in a reverse transcriptase reaction to prepare single-strand cDNA which can then be converted to double stranded cDNA. Suitable methods therefor include the S₁ nuclease method [cf. Efstratiadis, A., et al., (1976), *Cell*, 7, 279-288], the Gubler-Hoffman method [cf. Gubler, U. and Hoffman, B. J., (1983), *Gene*, 25, 263-269] and the Okayama-Berg method [cf. Okayama, H. and Berg, P., (1982), *Mol. Cell. Biol.*, 2, 161-170]. However, the preferred method involves the polymerase chain reaction [hereinafter referred to as PCR, cf. Saiki, R. K., et al., (1988), *Science*, 239, 487-49] using single-strand cDNA as the template, namely "RT PCR".

[0064] The double-strand cDNA obtained above may then be integrated into a cloning vector and the resulting recombinant vector can then be used to transform a micro-organism, such as *E. coli*. The transformant can be selected using tetracycline resistance or ampicillin resistance. If *E. coli* is used, then transformation may be effected by the Hanahan method [cf. Hanahan, D., (1983), *J. Mol. Biol.*, 166, 557-580]. Namely, the recombinant vector may be introduced into competent cells prepared by co-exposure to calcium chloride, magnesium chloride or rubidium chloride. If a plasmid is used as a vector, it is necessary that the plasmid harbors a drug-resistant gene, such as mentioned above. It is also possible to use other cloning vehicles, such as lambda phages.

[0065] In order to select transformants for those which carry cDNA encoding a subunit of an anti-Fas antibody of interest, various methods, such as those described below, can be used. When the cDNA of interest is specifically amplified by the above-mentioned RT-PCR, these steps may be omitted.

(1) Method by polymerase chain reaction

[0066] If all or part of the amino acid sequence of the desired protein has been elucidated, then sense and antisense oligonucleotide primers corresponding to parts of the amino acid sequence can be synthesized, and used in the polymerase chain reaction technique [cf. Saiki, R. K., et al. (1988), *Science*, 239, 487-49] to amplify the desired DNA fragment encoding the anti-human Fas monoclonal antibody light chain subunit and heavy chain subunit. The template DNA may be, for example, cDNA synthesized by reverse transcription from mRNA of the hybridoma producing the anti-human Fas monoclonal antibody HFE7A (FERMBP-5828).

[0067] The DNA fragment thus synthesized may either be directly integrated into a plasmid vector by using a commercially available kit or the like, or may be labelled with, for example, ^{32}P , ^{35}S or biotin, and then used as a probe for colony hybridization or plaque hybridization to obtain the desired clone.

[0068] Anti-Fas monoclonal antibody HFE7A that is preferable as an active ingredient in the pharmaceutical composition of the present invention is immunoglobulin G1 (hereinafter referred to as "IgG1") comprising a heavy chain (γ chain) subunit and a light chain (κ chain) subunit. The partial amino acid sequence of each of subunits mentioned above can be determined preferably by isolating each subunit by a well known method such as electrophoresis and column chromatography, and sequencing the N-terminal amino acid sequence of each subunit with an auto protein sequencer (for example, PPSQ-10 by Shimadzu Seisakusho, Corp.).

[0069] Harvesting of cDNA encoding each subunit of anti-human Fas monoclonal antibody from the appropriate transformants obtained above may be performed by well known techniques [cf. Maniatis, T., et al., in "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, NY, (1982)]. For example, the region of DNA encoding the desired subunit may be excised from plasmid DNA after separating the fraction corresponding to the vector DNA from cells.

(2) Screening using a synthetic oligonucleotide probe

[0070] If all or part of the amino acid sequence of the desired protein has been elucidated (the sequence can be that in any region of the protein, provided that is specific and contains continuous amino acids), oligonucleotides corresponding thereto may be synthesized, and used as a probe (after labelling with ^{32}P , ^{35}S , biotin or the like), namely, hybridized with DNA from the transformant which has been immobilized on a nitrocellulose filter to select positive strains. As the probe, there can be used one oligonucleotide which is designed considering the frequency of codons in a host, or a mixture of possible oligonucleotides. In the latter case, the number of oligonucleotides to be used can be reduced by using inosine.

[0071] DNA thus obtained may be sequenced by, for example, the Maxam-Gilbert chemical modification technique [cf. Maxam, A. M. and Gilbert, W. (1980) in "Methods in Enzymology" 65, 499-576], the dideoxy chain termination method [cf. Messing, J. and Vieira, J. (1982) *Gene*, 19, 269-276] or the like.

[0072] In recent years, there has been widely used automated DNA sequencers using a fluorogenic dye, for example Sequencerobot "CATALYST 800" and the model 373A DNA Sequencer, manufactured by Perkin-Elmer Japan, Inc.

[0073] By using systems such as those described above, determination of the DNA sequence can be performed efficiently and safely. Based on the data of the nucleotide sequences of the DNA of the present invention thus determined and the data of the N-terminal amino acid sequences of the heavy chain and the light chain thereof, the entire amino acid sequences of the heavy chain and the light chain of a monoclonal antibody of the present invention can be determined.

[0074] Construction of a mutant wherein one or more amino acids in an amino acid sequence is deleted may be performed, for example, by cassette mutagenesis [cf. Toshimitsu Kishimoto, "Shin-Seikagaku Jikken Kouza 2: Kakusan III Kumikae DNA Gijutsu", 242-251].

[0075] Such DNA sequences may be prepared by chemical synthesis using a conventional method, such as the phosphite triester method [cf. Hunkapiller, M., et al., (1984), *Nature*, 310, 105-111]. Codons for each amino acid themselves are known, and a specific codon for a desired amino acid may be selected arbitrarily, or by taking a frequency of a given codon in a host into account. Partial modification of the nucleotide sequence can be accomplished by conventional techniques, such as site-specific mutagenesis utilizing synthetic oligonucleotide primers encoding the desired modifications [cf. Mark, D. F., et al., (1984), *Proc. Natl. Acad. Sci. USA*, 81, 5662-5666].

[0076] Whether DNA can be hybridized with DNA encoding the light chain or the heavy chain of the anti-Fas monoclonal antibody that is preferable as an active ingredient in the pharmaceutical composition of the present invention can be determined, for example, by using a DNA probe labelled with (α - ^{32}P)dCTP or the like, for example, by the random primer method [cf. Feinberg, A. P. and Vogelstein, B. (1983), *Anal. Biochem.*, 132, 6-13], by the nick translation method [cf. Maniatis, T., et al., (1982), in "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, NY] or the like. A suitable technique is as follows.

[0077] First, the DNA to be determined is adsorbed onto a nitrocellulose membrane or a nylon membrane, for ex-

ample, being subjected to alkaline treatment if necessary, and then being fixed on the membrane by heating or UV irradiation. The membrane is next immersed in prehybridisation solution containing 6 x SSC (1 x SSC is a solution of 0.15 M NaCl and 0.015 M tri-sodium citrate), 5% v/v Denhardt solution and 0.1% v/v sodium dodecyl sulfate (SDS), and incubated at 55°C for 4 hours or more. Then, the probe previously prepared is added in similar prehybridisation solution to a final specific activity of 1×10^6 cpm/ml, followed by incubation at 60°C overnight. Subsequently, the membrane is washed at room temperature by repeated washing with 6 x SSC for 5 minutes and further with 2 x SSC for 20 minutes, and is then subjected to autoradiography.

[0078] By using the above method, DNA hybridisable with the DNA encoding the heavy or light chain of the anti-Fas monoclonal antibody that is preferable as an active ingredient in the pharmaceutical composition of the present invention can be isolated from any cDNA library or genomic library [cf. Maniatis, T., et al., (1982), "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, NY].

[0079] Integration of DNA thus obtained into an expression vector allows transformation of prokaryotic or eukaryotic host cells, thereby allowing the DNA to be expressed in the host cell.

[0080] Suitable prokaryotic host cells include, for example, *Escherichia coli*, *Bacillus subtilis*, and the like. In order to express the gene of interest in such host cells, these host cells may be transformed with a plasmid vector containing a replicon derived from a species compatible with the host, namely an origin of replication and a promoter sequence, such as lac UV5. These vectors preferably have sequences capable of conferring a selection phenotype on the transformed cell. A suitable strain of *E. coli* is strain JM109 derived from *E. coli* K12. Suitable vectors include pBR322 and the pUC series plasmids, without being limited thereto. Other known strains and vectors can also be utilized. Suitable promoters include the tryptophan (trp) promoter, the lactose promoter (lac), the tryptophan lactose promoter (tac), the lipoprotein promoter (lpp), the lambda (λ) PL promoter derived from bacteriophage, and the polypeptide chain elongation factor Tu (tufB) promoter, without being limited thereto.

[0081] A preferred strain of *Bacillus subtilis* is strain 207-25, and a preferred vector is pTUB228 [cf. Ohmura, K., et al., (1984), *J. Biochem.*, 95, 87-93], without being limited thereto. A suitable promoter is the regulatory sequence of the *Bacillus subtilis* α -amylase gene. If desired, the DNA sequence encoding the signal peptide sequence of α -amylase may be linked to the DNA of the present invention to enable extracellular secretion.

[0082] Eukaryotic hosts include cells from vertebrate and yeast species. An example of vertebrate cells used is the monkey COS-1 cell line [cf. Gluzman, Y., (1981), *Cell*, 23, 175-182]. Suitable yeast cell hosts include baker's yeast (*Saccharomyces cerevisiae*), methylotrophic yeast (*Pichia pastoris*) and fission yeast (*Schizosaccharomyces pombe*). The cells mentioned above are generally used as the host cell, but the host cell to be used is not limited thereto.

[0083] In general, the requirements for suitable expression vectors for vertebrate cells are that they comprise: a promoter, usually located upstream of the gene to be expressed; an RNA splicing site; a polyadenylation site; and a transcription termination sequence; and an origin of replication if necessary. A suitable plasmid is, for example, pSV2dhfr containing the SV40 early promoter [cf. Subramani, S., et al. (1981), *Mol. Cell. Bio.*, 1, 854-864], without being limited thereto.

[0084] Suitable expression vectors for yeasts contain, for example, the promoter of the alcohol dehydrogenase gene [cf. Bennettzen, J. L. and Hall, B. D., (1982), *J. Biol. Chem.*, 257, 3018-3025] or the promoter of a galactose metabolic enzyme (for example, gal 10) [cf. Ichikawa, K., et al. (1993), *Biosci. Biotech. Biochem.*, 57, 1686-1690], without being limited thereto. If desired, the DNA sequence encoding the signal peptide sequence of a yeast gene may be linked to the DNA to be expressed in order to enable extracellular secretion.

[0085] When COS-1 cells are used as a host cell, expression vectors suitably comprise the SV40 replication origin, enabling autonomous replication, a transcription promoter, a transcription termination signal and an RNA splicing site. The said expression vectors can be used to transform the COS-1 cells by any suitable method, such as the DEAE-dextran method [cf. Luthman, H. and Magnusson, G. (1983), *Nucleic Acids Res.*, 11, 1295-1308], the phosphate calcium-DNA coprecipitation method [cf. Graham, F. L. and Van der Eb, A. J., (1973), *Virology*, 52, 456-457] and the electric pulse electroporation method [cf. Neumann, E., et al., (1982), *EMBO J.*, 1, 841-845]. A desired transformant can be obtained by these methods.

[0086] Preferably, COS-1 cells are co-transfected with two expression vectors: one containing DNA encoding the heavy chain and the other containing DNA encoding the light chain, to provide a transformant producing the recombinant anti-Fas antibody. However, the method of producing the recombinant anti-Fas antibody is not limited thereto. For example, it is also possible to construct only one expression vector containing both the DNA encoding the heavy chain and the DNA encoding the light chain, which is expressed simultaneously, and to transfect COS-1 cells therewith.

[0087] Desired transformants obtained by the above methods may be cultured using conventional methods, the recombinant anti-Fas antibody being expressed either intra- or extra-cellularly. Suitable culture media include various commonly used media, depending on the host chosen. For example, suitable media for COS-1 cells include RPMI-1640 and Dulbecco's Modified Eagle Medium (DMEM), which can be supplemented with, as desired, fetal calf serum (FCS).

[0088] The culture temperature for culturing the transformant may be any suitable temperature which does not mark-

edly depress the protein synthesis capability of the cell, and is preferably in the range of 32 to 42°C, most preferably 37°C. If desired, culture may be effected in an atmosphere containing 1 to 10% (v/v) carbon dioxide.

[0089] The fraction containing the anti-Fas antibody protein produced intra- or extra-cellularly by the transformants as described above may be isolated and purified by various well known methods of separation according to the physical and chemical properties of the protein. Suitable specific methods of separation include: treatment with commonly used precipitating agents for protein; various methods of chromatography such as ultrafiltration, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography and high performance liquid chromatography (HPLC), dialysis and combination thereof.

[0090] According to the method described above, the highly pure recombinant, anti-Fas antibody can be readily produced in high yields.

[0091] In order to confirm that a recombinant anti-Fas antibody prepared by the above method specifically binds to Fas, ELISA may be preferably performed in a manner similar to that described above for the evaluation of antibody titers in immunized mice.

[0092] On the other hand, a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity, for example the compounds represented by the above formulae (I) to (XIX) can be produced according to the literature description referred to in the earlier explanation for each of the compounds. It is possible to determine whether other compounds have a folate antagonist activity or a dihydrofolate reductase inhibiting activity according to the methods for confirming a folate antagonist activity or a dihydrofolate reductase inhibiting activity, utilized in the literatures respectively.

[0093] The pharmaceutical composition of the present invention containing the above compounds as active ingredients can be used as an agent for prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis. Such a prophylactic or therapeutic agent may be administered in various forms. Examples of such forms include oral administration, with tablets, capsules, granules, powders, syrups or the like, or parenteral administration, with injection, dropping injection, suppositories or the like.

[0094] The amount of the anti-human Fas antibody and a dose of the compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity in the pharmaceutical composition of the present invention can vary depending on activity inherent in each antibody or each compound to be used. For example, when CH11 or HFE7A is used as the anti-human Fas antibody, and methotrexate is used as the compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity, it is preferable that the pharmaceutical composition of the present invention is prepared as a solution containing 0.1 to 100 ng/ml of CH11 or HFE7A and 0.05 to 5 nM of methotrexate, but the present invention is not limited thereto.

[0095] The dose will vary, depending on factors such as the condition, age and body weight of the patient, but usually it may be administered in an amount of from 0.1 mg to 1,000 mg at one time as the amount of anti-human Fas antibody by subcutaneous, intramuscular or intravenous injection.

[0096] The validity in treatment of the autoimmune disease or rheumatoid arthritis of the pharmaceutical composition of the present invention prepared as described above can be checked by culturing cells (for example, human lymphocyte cell stock HPB-ALL (cf. Morikawa, S., et al. (1978) Int. J. Cancer 21, 166-170 to reference), Jurkat (American Type Culture No. TIB-152), synovial cells originating from the rheumatoid arthritis patient or the like) in a medium to which the pharmaceutical composition of the present invention is added, and measuring viability by methods such as MTT assay (cf. Green, L.M., et al. (1984) J. Immunological Methods 70, 257-268) or XTT assay indicated in the following examples. The pharmaceutical composition of the present invention can induce apoptosis in self-reactive lymphocytes which is one of the main causes of an autoimmune disease and in synovial cells proliferating abnormally in the rheumatoid arthritis affected part at a lower dose of anti Fas antibody, compared with the case where only an anti-Fas antibody is administered, and thus it is effective in treatment of these autoimmune diseases or rheumatoid arthritis. It has been reported also in European patent Application Laid-open publication No. 0909816 that the composition containing the anti-Fas antibody accepted to be effective in the experiments using the above-mentioned cultured cells is actually effective for treatment of autoimmune disease and rheumatoid arthritis with results of the experiment using the animal experiment model.

BRIEF EXPLANATION OF THE DRAWINGS

[0097]

Fig. 1 is a graph showing a synergistic effect of anti-human Fas monoclonal antibody CH11 and methotrexate in inducing apoptosis in cells.

Fig. 2 is a graph showing a synergistic effect of anti-human Fas monoclonal antibody HFE7A and methotrexate in inducing apoptosis in cells.

Fig. 3 is a graph showing cell viability in the presence of methotrexate.

BEST MODE FOR CARRYING OUT THE INVENTION

[0098] The invention will now be illustrated in more detail with reference to the following Examples, but the present invention is not limited thereto.

Example 1

[0099] The anti-human Fas monoclonal antibody HFE7A or CH11 (manufactured by Igaku seibutsugaku kenkyusho K.K.) described in European patent Application Publication No. 0909816 was used as an anti-Fas antibody.

[0100] Human lymphocyte cell stock HPB-ALL (cf. Morikawa, S., et al. (1978) Int. J. Cancer 21, 166-170) was cultured in RPMI 1640 medium containing 10% FCS (manufactured by Gibco B.R.L. Corporation) at 37°C, in the presence of 5% carbon dioxide gas for three days, and 50 µl of the culture (2.5 x 10⁵ cells/50 µl) were dispensed into each well of a 96-well microplate (manufactured by Sumitomo Bakelite Co., Ltd.). Then, 50 µl of the RPMI medium containing methotrexate (manufactured by Sigma Chemical Company), and an anti-Fas antibody (CH11 or HFE7A, 0.001 mg/ml solution was serially diluted by three times) were added to each well, and was cultured at 37°C.

[0101] The cells in the plate to which CH11 was added as an anti-Fas antibody were kept to be cultured at 37°C overnight. On the other hand, the cells in the plate to which HFE7A was added were washed with the RPMI medium after being cultured for one hour, and then 100 µl/well of RPMI medium containing 1 µg/ml of anti-mouse IgG antibody (manufactured by Blosource corporation) were added. The cells were cultured at 37°C for one hour, and then they were washed with serum-free RPMI medium. Subsequently, 100 µl/well of RPMI medium containing 0.05 nM of methotrexate were added thereto, and the cells were cultured at 37°C overnight. Then, 50 µl of 25 µM PMS (phenazine methosulphate; Sigma Chemical Company), containing 1 mg/ml of XTT [2,3-bis(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxyanilide zwitterion; Sigma Chemical Company] (final concentrations: 250 µg/ml as for XTT and 5 µM as for PMS) were added to each well. The plate was then incubated for 3 hours at 37°C, and the absorbance at 450 nm of each well was measured, to calculate cell viability, using the reducing power of the mitochondria as the index.

[0102] The viability of the cells in each well was calculated according to the following equation:

$$\text{viability(\%)} = 100 \times (a-b)/(c-b)$$

wherein "a" is the absorbance of a test well, "b" is the absorbance of a well with no cells and c is the absorbance of a well with no antibody added.

[0103] As a result, it became clear that the apoptosis inducing activity of CH11 was significantly increased with addition of 0.05 nM or more of methotrexate (See Fig. 1. "MTX" in Fig. 1 represents methotrexate, hereinafter it represents the same). The apoptosis inducing activity of HFE7A was also increased with addition of 0.05 nM of methotrexate (See Fig. 2). When anti-Fas antibody was not added, but only methotrexate was added, there was almost no change in the viability of the cells (See Fig. 3).

[0104] It was shown that the apoptosis inducing activity of the anti-Fas antibody was reinforced by addition of methotrexate, and the number of the cells that may cause an autoimmune disease can be reduced with a lower dose of an anti-Fas antibody, compared with conventional methods.

Formulation example

[0105] The agent for prophylaxis and/or treatment of the present invention can be used in the form of an ampoule of a sterile solution or suspension which contains an anti-human Fas antibody and a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity in water or in another pharmaceutically acceptable solution. Specifically, for example, 0.5 mg of anti-human Fas antibody and methotrexate (final concentration: 0.05 nM) are dissolved in 1 liter of water for injection, sterilely filled into an ampoule and sealed.

[0106] Alternatively, a sterile powder (preferably, prepared by lyophilization of the anti-human Fas antibody and compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity) may be filled into an ampoule, which may then be diluted with a pharmaceutically acceptable solution when it is used.

Industrial Applicability

[0107] As described above, the present invention provides a novel pharmaceutical composition useful as an agent for prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis. According to the present invention, the amount of the anti-Fas antibody to be used can be reduced by using a compound having a folate antagonist activity

or a dihydrofolate reductase inhibiting activity and an anti-human Fas antibody together. Thereby, the possibility that a patient becomes tolerant to an anti-Fas antibody as a result of production of antibodies against the anti-Fas antibody in the patient's body or the like can be decreased, and thus the pharmaceutical composition of the present invention is useful as an excellent agent for prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis that can be used for a long time.

Claims

1. A pharmaceutical composition comprising an anti-human Fas antibody having an apoptosis inducing activity and a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity, as active ingredients.
2. The pharmaceutical composition according to Claim 1, wherein the anti-human Fas antibody having apoptosis inducing activity is a monoclonal antibody CH11, HFE7A or humanized antibodies thereof.
3. The pharmaceutical composition according to Claim 1 or 2, wherein the anti-human Fas antibody having apoptosis inducing activity is a monoclonal antibody CH11 or humanized antibodies thereof.
4. The pharmaceutical composition according to Claim 1 or 2, wherein the anti-human Fas antibody having apoptosis inducing activity is an anti-human Fas monoclonal antibody HFE7A produced by a mouse-mouse hybridoma HFE7A (FERMBP-5828) or humanized antibodies thereof.
5. The pharmaceutical composition according to any one of Claims 1 to 4, wherein the compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity is selected from the group consisting of: methotrexate, edatrexate, epiroprim, iometrexol, pyritrexim, trimetrexate, brodimoprim, MX-68, N-[4-{3-(2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-yl)propyl}benzoyl]-L-glutamic acid, N-[[5-{2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl-2-thienyl}carbonyl]-L-glutamic acid, (R)-N-[[5-{2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl-2-thienyl}carbonyl]-L-glutamic acid, N-((2,4-diamino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl)-2-thienylcarbonyl-L-glutamic acid, (S)-2-[[[4-carboxy-4-[[4-[[[(2,4-diamino-6-pteridinyl)methyl]-amino]benzoyl]amino]butyl]amino]carbonyl]benzoic acid, N-[4-{3-(2,4-diamino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl}benzoyl]-L-glutamic acid, 2,4-diamino-6-(N-(4-(phenylsulfonyl)benzyl)methylamino)quinazoline, 2,4-diamino-5-[4-{3-(4-aminophenyl-4-sulfonylphenylamino)propoxy-3,5-dimethoxybenzyl}pyrimidine, N-[4-{4-(2,4-diamino-5-pyrimidinyl)butyl}benzoyl]-L-glutamic acid, N-[4-{3-(2,4-diamino-5-pyrimidinyl)propyl}benzoyl]-L-glutamic acid, N-[4-{2-(2,4-diamino-6-pteridinyl)ethyl}benzoyl]-4-methylene-DL-glutamic acid and N-(1-methylethyl)-N'[3-(2,4,5-trichlorophenoxy)propoxy]imidodicarbonimidic diamide hydrochloride (PS15).
6. The pharmaceutical composition according to any one of Claims 1 to 5, wherein the compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity is methotrexate.
7. The pharmaceutical composition according to any one of Claims 1 to 6 that is an agent for prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis.




Fig.1




Fig.2




Fig.3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/03324

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl. ⁷ A61K39/395, 45/00, 31/519, 31/506, 31/517, 31/505, 31/5415, 31/155, A61P37/06, 29/00, 19/02//C07D475/08, 403/10, 471/04, 239/95, 487/04, 239/48, C07C279/26 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl. ⁷ A61K39/395, 45/00, 31/519, 31/506, 31/517, 31/505, 31/5415, 31/155, A61P37/06, 29/00, 19/02//C07D475/08, 403/10, 471/04, 239/95, 487/04, 239/48, C07C279/26 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS (STN), MEDLINE (STN), EMBASE (STN), BIOSIS (STN), REGISTRY (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MIZUTANI, Y. et al., "Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II)", JOURNAL OF UROLOGY, 1998, Vol.160, No.2, pp.561-70, especially, page 564, left column, lines 25-39; page 566, left column, lines 11-14	1-3, 6, 4, 5, 7
Y		
X	McGAHAN, Anne J. et al., "Chemotherapeutic drug-induced apoptosis in human leukemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system", Br. J. Haematol. 1998, Vol.101, No.3, pp.539-547, especially, Summary, Fig.6, Fig.7, and page 546, right column, lines 15-30	1, 6 2-5, 7
Y		
X	MIZUTANI, Youichi et al., "Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity", Cancer (N. Y.), 1997, Vol.79, No.6, pp.1180-1189 especially, page 1183, left column, lines 17-20	1, 6 2-5, 7
Y		
Y	EP, 866131, A2 (Sankyo Company Limited), 23 September, 1998 (23.09.98), the whole document & JP, 10-324699, A	2-5, 7
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 22 August, 2000 (22.08.00)		Date of mailing of the international search report 25 September, 2000 (05.09.00)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

EP 1180369 A1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/03324

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP, 709097, A1 (SANTEN PHARMACEUTICAL CO., LTD.), 01 May, 1995 (01.05.95), Claims & JP, 08-208515, A & US, 6086877, A	2-5,7
Y	EP, 909816, A1 (Sankyo Company Limited), 21 April, 1999 (21.04.99), Claims & JP, 11-171900, A	2-5,7
Y	Nobutoshi SERIZAWA, "Atarashii Kou Fas Monoclonal Koutai niyoru Chiryoyaku Kaihatsu eno Kokoromi", <i>Saishin Igaku</i> , April 1999, Vol.54, No.4, pp.917-924, especially, page 924, left column, lines 1-7	2-5,7
Y	"THE MERCK INDEX, Twelfth Edition", MERCK & CO., INC., WHITEHOUSE STATION NJ, 1996, pp.592-3, 3553.	2-5,7
Y	WO, 92/08461, A1 (PROTOS CORPORATION), 29 May, 1992 (29.05.92), the whole document & EP, 639075, A1 & JP, 07-509215, A	2-5,7
Y	WO, 86/05181, A1 (THE TRUSTEES OF PRINCETON UNIVERSITY), 12 September, 1986 (12.09.86), the whole document & EP, 215063, A1 & JP, 62-502535, A & US, 4684653, A	2-5,7
Y	EP, 21292, A1 (THE WELCOME FOUNDATION LIMITED), 07 January, 1981 (07.01.81), the whole document & JP, 56-018982, A & US, 4372957, A & US, 4661490, A & US, 4959474, A & US, 4897395, A	2-5,7
Y	"THE MERCK INDEX, Twelfth Edition", MERCK & CO., INC., WHITEHOUSE STATION NJ, 1996, p.1656, 9851	2-5,7
Y	"THE MERCK INDEX, Twelfth Edition", MERCK & CO., INC., WHITEHOUSE STATION NJ, 1996, p.126, 1401	2-5,7
Y	EP, 897724, A1 (Chugai Seiyaku Kabushiki Kaisha), 24 February, 1999 (24.02.99), the whole document & WO, 97/34606, A1 & JP, 09-309832, A & US, 6080737, A	2-5,7
Y	KOTAKE, Yoshihiko, "Synthesis and Antitumor Activities of Novel 6-5 Fused Ring Heterocycle Antifolates: N-(4-{.omega.-(2-Amino-4-substituted-6,7-dihydrocyclo penta[d]pyrimidin-5-yl)alkyl}benzoyl)-L-glutamic Acids", <i>J. Med. Chem.</i> , 1994, Vol.37, No.11, pp.1616-24	2-5,7
Y	FAESSEL, Helene M., "Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylolation", <i>Cancer Res.</i> 1998, Vol.58, No.14, pp.3036-3050	2-5,7

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/03324

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ROSOWSKY, Andre, "Synthesis and biological activity of methotrexate analogs with two acid groups and a hydrophobic aromatic ring in the side chain", J. Med. Chem., 1991, Vol.34, No.2, pp.574-9	2-5,7
Y	EP, 334636, A2 (TAKEDA CHEMICAL INDUSTRIES LTD.), 27 September, 1989 (27.09.89), the whole document & US, 4997838, A & JP, 02-167281, A & US, 5106974, A & US, 5296600, A & US, 5539113, A	2-5,7
Y	WO, 93/13079, A1 (AGOURON PHARMACEUTICALS, INC.), 08 July, 1993 (08.07.93), the whole document (Family: none)	2-5,7
Y	US, 4912112, A (Saarstickstoff-Patol GmbH Chem.- Pharm.-Fabrik), 27 May, 1990 (27.05.90), the whole document & DE, 3603577, A1 & EP, 231888, A2 & JP, 62-265272, A	2-5,7
Y	WO, 95/09845, A1 (ELI LILLY AND COMPANY), 13 April, 1995 (13.04.95), the whole document US, 5426110, A & EP, 722440, A1 & JP, 09-503509, A	2-5,7
Y	WO, 91/10666, A1 (NAIR, Madhavan G.), 25 July, 1991 (25.07.91), the whole document & US, 4996207, A & US, 5073554, A & JP, 04-505932, A & EP, 513068, A1	2-5,7
Y	HUGHES, Walter T. et al, "Anti-Pneumocystis carinii activity of PS-15, a new biguanide folate antagonist", Antimicrob. Agents Chemother., 1993, Vol.37, No.7, pp.1417-19	2-5,7
Y	GENESTIER, Laurent et al, "Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells", J. Clin. Invest., 1998, Vol.102, No.2, pp.322-328, especially, Abstract, page 327, right column, lines 9-30	2-5,7
Y	NISHIMURA-MORITA, Yoshiko et al, "Amelioration of systemic autoimmune disease by the stimulation of apoptosis-promoting receptor Fas with anti-Fas mAb", Int. Immunol. 1997, Vol.9, No.12, pp.1793-1799, especially, Abstract	2-5,7
Y	Koushi FUJISAWA et al., "Mouse Kansetsuen ni taisuru Kou Fas Kotai no Chiryo Kouka", Mol. Med. (Tokyo), 1996, Vol.33, No.11, pp.1254-1261, especially, page 1260, left column, line 16 to right column, line 12	2-5,7

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/03324

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FUJISAWA, Koushi et al., "Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-I tax transgenic mice", J. Clin. Invest., 1996, Vol.98, No.2, pp.271-278, especially, Abstract	2-5,7
Y	Sakai, K. et al, "Potential withdrawal of rheumatoid synovium by the induction of apoptosis using a novel in vivo model of rheumatoid arthritis", ARTHRITIS AND RHEUMATISM, 1998, Vol.41, No.7, pp.1251-7, especially, Summary	2-5,7
Y	HASUNUMA, Tomoko et al, "Induction of Fas-dependent apoptosis in synovial infiltrating cells in rheumatoid arthritis", Int. Immunol., 1996, Vol.8, No.10, pp.1595-1602, especially, Abstract, and page 1596, left column, lines 34-47	2-5,7
Y	SUMIDA, Takayuki et al., "Rheumatoid arthritis and apoptosis", Intern. Med., (Tokyo), 1998, Vol.37, No.2, pp.184-188, especially, Introduction	2-5,7
PX	MIZUTANI, Youichi et al., "Effect of anticancer agents on Fas-mediated cytotoxicity against bladder cancer cells", J. Infect. Chemother. 1999, Vol.5, No.3, pp.139-143, especially, page 140, left column, lines 26-28	1,6

Form PCT/ISA/210 (continuation of second sheet) (July 1992)